ArticleFrontiers in pediatrics2023
Case report: Accelerated regression of giant cardiac rhabdomyomas in neonates with low dose everolimus.
Article in Frontiers in pediatrics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 9 citations in OpenAlex.
- Everolimus and sirolimus in the treatment of cardiac rhabdomyomas in neonates.Pediatric research · 2025Pooled it
- Drug review: mTOR-inhibitor therapy in fetal cardiac rhabdomyoma-a tightrope walk.Frontiers in pediatrics · 2025Pooled it
- Early use of everolimus for neonatal cardiac rhabdomyoma: a pharmacotherapeutic case with pharmacist-led monitoring.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2026Article
- Coincidence or Association?: Pacing for Sinus Node Dysfunction in a Newborn With a Giant Ventricular Rhabdomyoma.JACC. Case reports · 2025Article
- Prenatal Diagnosis and Management of Tuberous Sclerosis Complex with Cardiac Rhabdomyoma: A Case Report Highlighting the Role of Sirolimus and Postnatal Complications.Diagnostics (Basel, Switzerland) · 2025Article
- Exploring Cardiovascular Involvement in Tuberous Sclerosis: Insights for Pediatric Clinicians.Children (Basel, Switzerland) · 2024Review
- Three-Year Follow-Up after Intrauterine mTOR Inhibitor Administration for Fetus with TSC-Associated Rhabdomyoma.International journal of molecular sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiac rhabdomyoma (CRHM) is the principal cardiac tumor in children and is most often associated with tuberous sclerosis complex (TSC). Mutations in the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.